{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:37:49Z","timestamp":1789562269096,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Purpose<\/jats:title>\n<jats:p>To evaluate the safety, feasibility, and preliminary efficacy of yttrium-90 (<jats:sup>90<\/jats:sup>Y) radioembolization (RE) as a minimally invasive treatment in a canine model with presumed spontaneous brain cancers.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Materials<\/jats:title>\n<jats:p>Three healthy research dogs (R1\u2013R3) and five patient dogs with spontaneous intra-axial brain masses (P1\u2013P5) underwent cerebral artery RE with <jats:sup>90<\/jats:sup>Y glass microspheres (TheraSphere). <jats:sup>90<\/jats:sup>Y-RE was performed on research dogs from the unilateral internal carotid artery (ICA), middle cerebral artery (MCA), and posterior cerebral artery (PCA) while animals with brain masses were treated from the ICA. Post-treatment <jats:sup>90<\/jats:sup>Y PET\/CT was performed along with serial neurological exams by a veterinary neurologist. One month after treatment, research dogs were euthanized and the brains were extracted and sent for microdosimetric and histopathologic analyses. Patient dogs received post-treatment MRI at 1-, 3-, and 6-month intervals with long-term veterinary follow-up.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The average absorbed dose to treated tissue in R1\u2013R3 was 14.0, 30.9, and 73.2\u2009Gy, respectively, with maximum doses exceeding 1000\u2009Gy. One month after treatment, research dog pathologic analysis revealed no evidence of cortical atrophy and rare foci consistent with chronic infarcts, e.g., &lt;\u20092-mm diameter. Absorbed doses to masses in P1\u2013P5 were 45.5, 57.6, 58.1, 45.4, and 64.1\u2009Gy while the dose to uninvolved brain tissue was 15.4, 27.6, 19.2, 16.7, and 33.3\u2009G, respectively. Among both research and patient animals, 6 developed acute neurologic deficits following treatment. However, in all surviving dogs, the deficits were transient resolving between 7 and 33\u2009days post-therapy. At 1 month post-therapy, patient animals showed a 24\u201394% reduction in mass volume with partial response in P1, P3, and P4 at 6\u2009months post-treatment. While P2 initially showed a response, by 5\u2009months, the mass had advanced beyond pre-treatment size, and the dog was euthanized.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>This proof of concept demonstrates the technical feasibility and safety of <jats:sup>90<\/jats:sup>Y-RE in dogs, while preliminary, initial data on the efficacy of <jats:sup>90<\/jats:sup>Y-RE as a potential treatment for brain cancer is encouraging.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13550-020-00679-1","type":"journal-article","created":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T10:03:15Z","timestamp":1597658595000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Yttrium-90 radioembolization as a possible new treatment for brain cancer: proof of concept and safety analysis in a canine model"],"prefix":"10.1186","volume":"10","author":[{"given":"Alexander S.","family":"Pasciak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasicha","family":"Manupipatpong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinand K.","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Gainsburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Krimins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Christine","family":"Zink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory F.","family":"Brayton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meaghan","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Sage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle R.","family":"Donahue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Dreher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dara L.","family":"Kraitchman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford R.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,17]]},"reference":[{"key":"679_CR1","doi-asserted-by":"crossref","unstructured":"Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS Statistical Report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol. 2015;17:iv1-iv62.","DOI":"10.1093\/neuonc\/nov189"},{"key":"679_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, Van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987\u201396.","journal-title":"N Engl J Med."},{"key":"679_CR3","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1200\/JCO.2007.15.7164","volume":"26","author":"A Murat","year":"2008","unstructured":"Murat A, Migliavacca E, Gorlia T, et al. Stem cell-related \u201cself-renewal\u201d signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol. 2008;26:3015\u201324.","journal-title":"J Clin Oncol."},{"key":"679_CR4","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/nature05236","volume":"444","author":"S Bao","year":"2006","unstructured":"Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756\u201360.","journal-title":"Nature."},{"key":"679_CR5","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nature11287","volume":"488","author":"J Chen","year":"2012","unstructured":"Chen J, Li Y, Yu TS, et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012;488:522\u20136.","journal-title":"Nature."},{"key":"679_CR6","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.celrep.2017.10.030","volume":"21","author":"S Darmanis","year":"2017","unstructured":"Darmanis S, Sloan SA, Croote D, et al. Single-cell RNA-seq analysis of infiltrating neoplastic cells at the migrating front of human glioblastoma. Cell Rep. 2017;21:1399\u2013410.","journal-title":"Cell Rep."},{"key":"679_CR7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/00006123-199608000-00001","volume":"39","author":"A Giese","year":"1996","unstructured":"Giese A, Westphal M. Glioma invasion in the central nervous system. Neurosurgery. 1996;39:235\u201352.","journal-title":"Neurosurgery."},{"key":"679_CR8","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/1097-0142(19830915)52:6<997::AID-CNCR2820520612>3.0.CO;2-2","volume":"52","author":"CH Chang","year":"1983","unstructured":"Chang CH, Horton J, Schoenfeld D, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint radiation therapy oncology group and eastern cooperative oncology group study. Cancer. 1983;52:997\u20131007.","journal-title":"Cancer."},{"key":"679_CR9","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/bjc.2011.123","volume":"104","author":"YR Lawrence","year":"2011","unstructured":"Lawrence YR, Wang M, Dicker AP, et al. Early toxicity predicts long-term survival in high-grade glioma. Br J Cancer. 2011;104:1365\u201371.","journal-title":"Br J Cancer."},{"key":"679_CR10","doi-asserted-by":"crossref","unstructured":"Shirazi HA, Grimm S, Raizer J, Mehta MP. Combined modality approaches in the management of adult glioblastoma. Front Oncol. 2011;1.","DOI":"10.3389\/fonc.2011.00036"},{"key":"679_CR11","doi-asserted-by":"crossref","unstructured":"Kleinberg L, Yoon G, Weingart JD, et al. Imaging after GliaSite brachytherapy: prognostic MRI indicators of disease control and recurrence. Int J Radiat Oncol Biol Phys. 2009.","DOI":"10.1016\/j.ijrobp.2008.12.074"},{"key":"679_CR12","volume-title":"Shaffer JL, et al","author":"JL Shah","year":"2018","unstructured":"Shah JL, Li G. Shaffer JL, et al. Neurosurgery: Stereotactic radiosurgery and hypofractionated radiotherapy for glioblastoma; 2018."},{"key":"679_CR13","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.ijrobp.2004.09.004","volume":"60","author":"AS Kennedy","year":"2004","unstructured":"Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C. Pathologic response and microdosimetry of 90Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 2004;60:1552\u201363.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"679_CR14","unstructured":"Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med. 2006."},{"key":"679_CR15","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1002\/hep.26382","volume":"58","author":"R Salem","year":"2013","unstructured":"Salem R, Mazzaferro V, Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives. Hepatology. 2013;58:2188\u201397.","journal-title":"Hepatology."},{"key":"679_CR16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2009.09.006","volume":"138","author":"R Salem","year":"2010","unstructured":"Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138:52\u201364.","journal-title":"Gastroenterology."},{"key":"679_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0167-8140(87)80055-5","volume":"10","author":"UF Rosenow","year":"1987","unstructured":"Rosenow UF, Findlay PA, Wright DC. The NCI-atlas of dose distributions for regular 125 I brain implants. Radiother Oncol. 1987;10:127\u201339.","journal-title":"Radiother Oncol."},{"key":"679_CR18","doi-asserted-by":"crossref","unstructured":"Pasciak AS, Abiola G, Liddell RP, et al. The number of microspheres in Y90 radioembolization directly affects normal tissue radiation exposure. Eur J Nucl Med Mol Imaging. 2019.","DOI":"10.1007\/s00259-019-04588-x"},{"key":"679_CR19","doi-asserted-by":"crossref","unstructured":"Pasciak AS, Bourgeois AC, Bradley YC. A comparison of techniques for 90Y PET\/CT image-based dosimetry following radioembolization with resin microspheres. Front Oncol. 2014;4 MAY:121.","DOI":"10.3389\/fonc.2014.00121"},{"key":"679_CR20","first-page":"1209","volume":"47","author":"SA Gulec","year":"2006","unstructured":"Gulec SA, Mesoloras G, Stabin M. Dosimetric techniques in 90Y-microsphere therapy of liver cancer: the MIRD equations for dose calculations. J Nucl Med. 2006;47:1209\u201311.","journal-title":"J Nucl Med."},{"key":"679_CR21","doi-asserted-by":"crossref","unstructured":"Crookston NR, Pasciak AS, Abiola G, Donahue D, Weiss CR, Frey EC. Verification of a method to detect glass microspheres via micro-CT. Med Phys. 2019;Accepted-i.","DOI":"10.1002\/mp.13874"},{"key":"679_CR22","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/00004032-199410000-00004","volume":"67","author":"KF Eckerman","year":"1994","unstructured":"Eckerman KF, Westfall RJ, Ryman JC, Cristy M. Availability of nuclear decay data in electronic form, including beta spectra not previously published. Health Phys. 1994;67:338\u201345.","journal-title":"Health Phys."},{"key":"679_CR23","unstructured":"Icru 44.; 1994."},{"key":"679_CR24","volume-title":"Heit JJ","author":"TR Geisbush","year":"2019","unstructured":"Geisbush TR, Marks MP. Heit JJ. Interv Neuroradiol: Cerebral foreign body reaction due to hydrophilic polymer embolization following aneurysm treatment by pipeline flow diversion device; 2019."},{"key":"679_CR25","doi-asserted-by":"crossref","unstructured":"Meiers C, Abebe Y, Alberto N, et al. Cerebral granulomatous inflammation secondary to hydrophilic polymer embolization following thrombectomy. Am J Case Rep. 2017.","DOI":"10.12659\/AJCR.902598"},{"key":"679_CR26","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/vco.12401","volume":"16","author":"SJ Moirano","year":"2018","unstructured":"Moirano SJ, Dewey CW, Wright KZ, Cohen PW. Survival times in dogs with presumptive intracranial gliomas treated with oral lomustine: a comparative retrospective study (2008-2017). Vet Comp Oncol. 2018;16:459\u201366.","journal-title":"Vet Comp Oncol."},{"key":"679_CR27","volume-title":"N\u00f6lte I","author":"M Bendszus","year":"2005","unstructured":"Bendszus M, Monoranu CM, Sch\u00fctz A. N\u00f6lte I. Solymosi L. Neurologic complications after particle embolization of intracranial meningiomas. Am J Neuroradiol: Vince GH; 2005."},{"key":"679_CR28","doi-asserted-by":"crossref","unstructured":"Carli DFM, Sluzewski M, Beute GN, Van Rooij WJ. Complications of particle embolization of meningiomas: frequency, risk factors, and outcome. Am J Neuroradiol. 2010.","DOI":"10.3174\/ajnr.A1754"},{"key":"679_CR29","doi-asserted-by":"crossref","unstructured":"Taylor CL, Dutton K, Rappard G, et al. Complications of preoperative embolization of cerebral arteriovenous malformations. J Neurosurg. 2004.","DOI":"10.3171\/jns.2004.100.5.0810"},{"key":"679_CR30","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.2967\/jnumed.113.135301","volume":"55","author":"S Walrand","year":"2014","unstructured":"Walrand S, Hesse M, Jamar F, Lhommel R. A hepatic dose-toxicity model opening the way toward individualized radioembolization planning. J Nucl Med. 2014;55:1317\u201322.","journal-title":"J Nucl Med."},{"key":"679_CR31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2967\/jnumed.113.126839","volume":"55","author":"S Walrand","year":"2014","unstructured":"Walrand S, Hesse M, Chiesa C, Lhommel R, Jamar F. The low hepatic toxicity per gray of 90Y glass microspheres is linked to their transport in the arterial tree favoring a nonuniform trapping as observed in posttherapy PET imaging. J Nucl Med. 2014;55:135\u201340.","journal-title":"J Nucl Med."},{"key":"679_CR32","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ejmp.2015.04.004","volume":"31","author":"S Girst","year":"2015","unstructured":"Girst S, Marx C, Br\u00e4uer-Krisch E, et al. Improved normal tissue protection by proton and X-ray microchannels compared to homogeneous field irradiation. Phys Medica. 2015;31:615\u201320.","journal-title":"Phys Medica."},{"key":"679_CR33","doi-asserted-by":"crossref","unstructured":"Sch\u00fcltke E, Balosso J, Breslin T, et al. Microbeam radiation therapy - grid therapy and beyond: a clinical perspective. Br J Radiol. 2017;90.","DOI":"10.1259\/bjr.20170073"},{"key":"679_CR34","doi-asserted-by":"crossref","unstructured":"Dilmanian FA, Krishnan S, McLaughlin WE, et al. Merging orthovoltage X-ray minibeams spare the proximal tissues while producing a solid beam at the target. Sci Rep. 2019;9.","DOI":"10.1038\/s41598-018-37733-x"},{"key":"679_CR35","doi-asserted-by":"crossref","unstructured":"Willowson KP, Tapner M, The QUEST Investigator Team, et al. A multicentre comparison of quantitative 90Y PET\/CT for dosimetric purposes after radioembolization with resin microspheres: the QUEST Phantom Study. Eur J Nucl Med Mol Imaging. 2015;42:1202-1222.","DOI":"10.1007\/s00259-015-3059-9"}],"updated-by":[{"DOI":"10.1186\/s13550-020-00691-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000}}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-020-00679-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-020-00679-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-020-00679-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T23:19:34Z","timestamp":1629155974000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-020-00679-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,17]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["679"],"URL":"https:\/\/doi.org\/10.1186\/s13550-020-00679-1","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13550-020-00691-5","asserted-by":"object"}]},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,17]]},"assertion":[{"value":"28 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via the original article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Johns Hopkins Animal Care and Use Committee. This article does not contain any studies with human participants performed by any of the authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors ASP, CRW, and DLK have received research grants from Biocompatibles PLC. MRD is an employee of Biocompatibles PLC. The remaining authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"96"}}